Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
37 hedge funds and large institutions have $9.16M invested in Lumos Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
6% more funds holding
Funds holding: 35 → 37 (+2)
60% less capital invested
Capital invested by funds: $23M → $9.16M (-$13.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$789K |
| 2 |
SC
Shay Capital
New York
|
+$327K |
| 3 |
Millennium Management
New York
|
+$131K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$117K |
| 5 |
VF
Virtu Financial
New York
|
+$69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$749K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$412K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$295K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$262K |
| 5 |
Renaissance Technologies
New York
|
-$114K |
LUMO Hedge Fund Activity: Q4 2022 in Review
37 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2022, worth a combined $9.16M — down 60% from $23M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LUMO positions and 2 closed out — a net gain of 5 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $789K. The largest seller was Goldman Sachs, cutting an estimated $749K.
- 37 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2022, up from 35 in Q3 2022.
- Funds reported $9.16M of Lumos Pharma, Inc. Common Stock stock for Q4 2022, down 60% quarter-over-quarter.
- 7 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2022 and 2 closed out, a net change of +5 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2022 was Jefferies Financial Group, an estimated $789K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2022 was Goldman Sachs, an estimated $749K sold.
Based on aggregated 13F filings for Q4 2022.